secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265708
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q3 net income $8.2M on VOWST gain; cash runway through Q2 2026; SER-155 Phase 2 protocol finalized pending funding
--------------------------------------------------------------------------------

- Net income from continuing ops $8.2M vs loss of $51.0M in Q3 2024, driven by $27.2M gain on VOWST sale.
- Cash and equivalents $47.6M; expects to fund operations only through Q2 2026, noting ongoing capital needs.
- FDA feedback received; SER-155 Phase 2 protocol for BSI prevention in allo-HSCT being finalized, pending study funding.
- CARB-X grant of up to $3.6M awarded for oral liquid formulation of SER-155; IST in irEC initial results expected early 2026.
- Cost-reduction measures implemented including workforce decrease; R&D expense $12.6M, G&A $9.5M in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525265708/0001193125-25-265708-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525265708/d27174d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265708

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer